Skip to main content

Table 1 Patient’s BMI, chemotherapy doses given and performance status

From: From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report

Year Month BMI Treatment Dose Performance status
2011   31.2    
2013 Feb 29.4 FLOX C1 Oxaliplatin: 150 mg Fluorouracil: 950 mg Calciumfolinat: 110 mg 0
  March 28.7 FLOX C2 Oxaliplatin: 140 mg Fluorouracil: 900 mg Calciumfolinat: 100 mg 1
  April 27.8 FLOX C3 Oxaliplatin: 120 mg Fluorouracil: 720 mg Calciumfolinat: 100 mg 1
  June 29.2 Capecitabine 500mgx1 1-2
  July   Capecitabine/ Bevacizumab C1 500 mg × 2/ 350 mg 1-2
  Aug   Capecitabine/ Bevacizumab C2 500 mg × 2/ 350 mg 0-1
    Capecitabine/ Bevacizumab C3 500 mg × 2/ 350 mg  
  Sept   Capecitabine/ Bevacizumab C4 500 mg × 2/ 350 mg  
    Capecitabine/ Bevacizumab C5 500 mg × 2/ 350 mg  
  Oct 29.8 Capecitabine/ Bevacizumab C6 500 mg × 2/ 350 mg 0-1
    Capecitabine/ Bevacizumab C7 500 mg × 2/ 350 mg  
2014 Jan 31.2    0
\